EUVIMEDEUVIMED entdecken
Crossref

Juvenile Idiopathic Arthritis: A Deep Dive into Pediatric Autoimmune Arthritis

Sanika Malusare

International Journal of Pharmaceutical Sciences Review and Research · 2026-03 · 86 (3)

DOI: 10.47583/ijpsrr.2026.v86i3.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmaceutical Sciences Review and Research, 2026-03. Verfasst von Sanika Malusare.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Arthritis is an autoimmune disease that causes inflammation of the joints, with seven major types identified.One of these is Juvenile Idiopathic Arthritis (JIA), which begins before the age of 16 years.JIA is further classified into six subtypes based on clinical and laboratory findings: systemic, oligoarticular, polyarticular with or without rheumatoid factor, enthesitis-related arthritis (ERA), psoriatic arthritis, and undifferentiated arthritis.Among these, polyarticular JIA is the most common type seen in children.Although the exact cause of JIA remains unknown, it cannot be completely prevented; however, adopting a healthy lifestyle, preventing infections, early diagnosis, and proper management can help reduce its severity and complications.Diagnosis varies depending on the subtype, for example, anti-CCP antibodies are used for polyarticular JIA, while HLA-B27 testing and MRI of joints aid in diagnosing ERA.Management strategies have evolved significantly: initially, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids were the primary treatments, but the introduction of biologic medications has greatly improved outcomes.Agents such as abatacept and tocilizumab have shown particular benefit in polyarticular JIA, while methotrexate, TNF inhibitors, and abatacept are effective in treating JIA-related uveitis.Looking ahead, the future of JIA treatment is moving towards more targeted, personalized, and less toxic therapies, including JAK inhibitors, IL-17/23 blockers, stem cell therapy, microbiome-based interventions, and nanomedicine.Early diagnosis and comprehensive management are crucial for preventing joint damage and improving long-term outcomes and adopting a healthy lifestyle, preventing infections, early diagnosis, and proper management can help reduce its severity and complications.Continued research on immunogenetics and novel biologics holds promise for personalized and more effective therapies in the future.

Zitieren

APA

Malusare, S. (2026). Juvenile Idiopathic Arthritis: A Deep Dive into Pediatric Autoimmune Arthritis. International Journal of Pharmaceutical Sciences Review and Research, 86(3). https://doi.org/10.47583/ijpsrr.2026.v86i3.012

Vancouver

Malusare S. Juvenile Idiopathic Arthritis: A Deep Dive into Pediatric Autoimmune Arthritis. International Journal of Pharmaceutical Sciences Review and Research. 2026;86(3). doi:10.47583/ijpsrr.2026.v86i3.012

BibTeX
@article{Malusare2026,
  author = {Malusare, Sanika},
  title = {Juvenile Idiopathic Arthritis: A Deep Dive into Pediatric Autoimmune Arthritis},
  journal = {International Journal of Pharmaceutical Sciences Review and Research},
  year = {2026},
  volume = {86},
  number = {3},
  doi = {10.47583/ijpsrr.2026.v86i3.012}
}
Kostenlos starten →